Review: Practical considerations in ovarian cancer chemotherapy

A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group

(2017) D. S. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study

(2017) D. Matei et al.   JOURNAL OF CLINICAL ONCOLOGY

AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

(2017) P. C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel in Patients With Suboptimal Residual Epithelial Ovarian or Primary Peritoneal Cancer

(2010) Keiichi Fujiwara et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009

(2009) Amy D. Tiersten et al.   GYNECOLOGIC ONCOLOGY

Intraperitoneal chemotherapy for ovarian cancer: 2009 goals

(2009) Joan L. Walker   GYNECOLOGIC ONCOLOGY

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial

(2009) Maurie Markman et al.   GYNECOLOGIC ONCOLOGY

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

(2009) Ursula A. Matulonis et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

(2009) Michael A. Bookman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1

(2009) Sergio Pecorelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy

(2008) Debra L. Richardson et al.   GYNECOLOGIC ONCOLOGY

Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

(2008) Debra L. Richardson et al.   GYNECOLOGIC ONCOLOGY

Phase II Study of Carboplatin and Pemetrexed for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer

(2008) Ursula A. Matulonis et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

(2007) Agustin A. Garcia et al.   JOURNAL OF CLINICAL ONCOLOGY